Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Collagen type XXIII alpha 1 chain (COL23A1) is a type II transmembrane protein and member of the nonfibrillar transmembranous collagen family[1][4]. It is encoded by the COL23A1 gene and is structurally related to collagens XIII and XXV. COL23A1 is found in both membrane-bound and shed (soluble) forms, the latter produced by proteolytic cleavage via furin protease[6]. Expression occurs in several adult and developing tissues, including epidermis, tongue, gut, lung, brain, kidney, and cornea[1]. COL23A1 is implicated in cell adhesion, primarily through interaction with integrin α2β1, and has been associated with tumor growth, survival, and metastasis in cancers such as non-small cell lung carcinoma and prostate cancer, where it may serve as a useful biomarker for detection and monitoring[1][4][6]. While fundamental biological functions continue to be characterized, its activities parallel those of other transmembrane collagen family members[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Collagen type XXIII alpha 1 chain (COL23A1).